Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2483-2496

  Youshia, John ^a   Kamel, Amany O ^a   Shamy, Abdelhameed El ^a   Mansour, Samar ^a  

^a Ain Shams University   (Egypt)

Author keywords

Cetostearyl alcohol; Factorial design; Heterolipids; Methazolamide; Nanostructured lipid matrices; Ocular delivery

Indexed keywords

CETOSTEARYLIC ALCOHOL; GLYCEROL BEHENATE; METHAZOLAMIDE; POLYSORBATE 80;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; ELECTRON MICROSCOPY; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; NANOANALYSIS; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; SUSTAINED DRUG RELEASE; ULTRASOUND; X RAY DIFFRACTION; ZETA POTENTIAL;

ADMINISTRATION, OPHTHALMIC; ANALYSIS OF VARIANCE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; INTRAOCULAR PRESSURE; LIPIDS; METHAZOLAMIDE; NANOPARTICLES; PARTICLE SIZE; POLYSORBATES; RABBITS; TIME FACTORS;

EID: 84870364134     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28307     Document Type: Article

References (41)

1. Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release. 2000;63(1-2):135-140.
2. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1981;16(1):75-93.
3. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
4. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release. 2004;95(2):217-227.
5. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3): 165-196.
6. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355(1-2):307-313.
7. Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm. 2004;58(2):343-356.
8. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
9. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199(2):167-177.
10. Attama AA, Schicke BC, Müller-Goymann CC. Further characterization of theobroma oil-beeswax admixtures as lipid matrices for improved drug delivery systems. Eur J Pharm Biopharm. 2006;64(3):294-306.
11. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
12. Friedlaender MH, Takruri H, inventor; Riolan Tehcnologies, Inc, assignee. Compositions, methods, and kits for treating dry eye. United States Patent 20070259021. November 8, 2007.
13. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16(8):730-742.
14. Edelhauser HF, Maren TH. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol. 1988;106(8):1110-1115.
15. Fridriksdóttir H, Loftsson T, Stefánsson E. Formulation and testing of methazolamide cyclodextrin eye drop solutions. J Control Release. 1997;44(1):95-99.
16. Chen R, Qian Y, Li R, et al. Methazolamide calcium phosphate nanoparticles in an ocular delivery system. Yakugaku Zasshi. 2010;130(3): 419-424.
17. Qian Y, Wang F, Li R, Zhang Q, Xu Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev Ind Pharm. 2010;36(11):1340-1347.
18. Li R, Jiang S, Liu D, et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul. 2011;28(2):134-141.
19. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1-14.
20. Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials. 2003;24(10):1781-1785.
21. Nasr M, Mansour S, Mortada ND, El Shamy AA. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS Pharm Sci Tech. 2008;9(1):154-162.
22. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm Sci Tech. 2007;8(1):1.
23. Winum JY, Casini A, Mincione F, et al. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004;14(1):225-229.
24. Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm. 2000;198(1):29-38.
25. Hazleton LW. Relation of surface-active properties of irritation of the rabbit eye. Proc Sci Sect T G A. 1952:17-18.
26. Klang S, Frucht-Pery J, Hoffman A, Benita S. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J Pharm Pharmacol. 1994;46(12):986-993.
27. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur J Pharm Biopharm. 2007;67(1):48-57.
28. Sanna V, Caria G, Mariani A. Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of econazole nitrate. Powder Technology. 2010;201(1):32-36.
29. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4):286-296.
30. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2010;20(2):115-123.
31. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61-73.
32. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces. 2010;81(2):412-421.
33. Schubert MA, Müller-Goymann CC. Characterisation of surfacemodified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm. 2005;61(1-2):77-86.
34. Attama AA, Müller-Goymann CC. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid. Int J Pharm. 2007;334(1-2):179-189.
35. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine. 2010;6(6):753-759.
36. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149-155.
37. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95(3):627-638.
38. Lv Q, Yu A, Xi Y, et al. Development and evaluation of penciclovirloaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1-2):191-198.
39. Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int J Pharm. 1999;182(1):59-69.
40. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev. 2008;60(15): 1663-1673.
41. Katragadda S, Talluri RS, Mitra AK. Modulation of P-glycoproteinmediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J Ocul Pharmacol Ther. 2006;22(2):110-120.